Skip navigation

This site is intended for US healthcare professionals only.

Request Representative/Samples

For patients weighing ≥50 kg with partial-onset seizures and as adjunctive therapy for primary generalized tonic‑clonic seizures more in one The established efficacy and tolerability
of lacosamide…
in a single daily dose

Not an actual patient.
Request Representative/Samples

Steady 24-hour delivery with fewer fluctuations1

Proven XR bead technology achieves once-daily dosing1

Bioequivalent to lacosamide at steady-state blood levels1

Once-Daily Dosing
Once-daily MOTPOLY XR is bioequivalent to twice-daily lacosamide1
Learn More
24-hr Steady-State Delivery
Built-in time-release technology delivers steady blood levels1
Learn More
Important Treatment Issues
Comorbidities, polypharmacy, and lifestyle may play a role when considering MOTPOLY XR for your adult patients
Learn More
Established Efficacy
Lacosamide demonstrated significant control of partial-onset seizures with or without secondary generalization and significant control of primary generalized tonic‑clonic seizures as adjunctive therapy2,3
Learn More
Proven Safety
Well-established safety and tolerability profile with low risk of effects on cognition4,5
Learn More

Click here to contact Aucta Pharmaceuticals Medical Information or call 1-800-655-9902.

INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.
  • MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
  • Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction. Closely monitor these patients.
  • MOTPOLY XR may cause syncope.
  • Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

USE IN SPECIFIC POPULATIONS:

  • Dose adjustment is recommended for severe renal impairment and mild or moderate hepatic impairment. Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.
  • Use is not recommended in severe hepatic impairment.
  • Based on animal data, MOTPOLY XR may cause fetal harm if used in pregnancy.

Please refer to the full Prescribing Information and Medication Guide for MOTPOLY XR for additional important information.

References:
1. Data on file, Aucta Pharmaceuticals; 2022. 2. Chung S, Ben-Menachem E, Sperling MR, et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs. 2010;24(12):1041–1054. 3. Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55(7):1088-1098. 4. Vimpat [package insert]. Smyrna, GA: UCB, Inc.; 2021. 5. Biton V, Gil-Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav. 2015;52:119-127.

You are about to leave the Motpoly XR healthcare provider website and will be visiting the Motpoly XR patient website to view the copay information.

Leave site

To request a visit from a representative or to receive samples:

Phone Icon

sales.support@usauctapharma.com